Results 201 to 210 of about 1,127,916 (265)

Exploratory analysis of tumor budding density in resected synchronous and metachronous colorectal liver metastases. [PDF]

Front Oncol
Petrović N, Kukić B, Šolajić N, Maletin N, Kolarov Bjelobrk I, Radić J, Đermanović A, Nikolić I.   +7 more
europepmc   +1 more source

Synergistic p53 Pathway Activation Through Sono‐Gene Therapy Induced by Ultrasound‐Triggered Theranostic Mesoporous Nanoparticles

Advanced Science, EarlyView.
Schematic representation of ultrasound‐mediated ICG/siCD24@MSN‐LCD from nanostructure to synergistic sono‐gene therapy. This nanoplatform targets ASGPR via the LCD shell, which dissociates to release loaded ICG and siCD24. The core mechanism involves ultrasound‐guided sonodynamic therapy by ICG and CD24 knockdown by siCD24, both activating the p53 axis
Yading Zhao, Lu Guo, Dandan Shi, Xiao Sun, Mengmeng Shang, Song Ning, Shuting Huang, Xiaoxuan Wang, Rui Liu, Yuye Fu, Suyun Li, Jie Li   +11 more
wiley   +1 more source

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases.

JAMA Oncol
Kataoka K, Ito K, Nakamura Y, Watanabe J, Akazawa N, Nagata J, Yokota M, Kato K, Kotaka M, Hashimoto T, Yamazaki K, Kagawa Y, Mishima S, Ando K, Miyo M, Yukami H, Fungtammasan A, Sharma S, Ortiz JB, Rabinowitz M, Lentz RW, Jurdi A, Liu MC, Aleshin A, Kotani D, Bando H, Taniguchi H, Takemasa I, Kato T, Yoshino T, Oki E, CIRCULATE-Japan Group.   +31 more
europepmc   +1 more source

Liver Transplantation for Unresectable Colorectal Liver Metastases: Evidence, Patient Selection, and Clinical Implementation. [PDF]

Cancers (Basel)
Smedman TM, Fretland ÅA, Dueland S, Solheim J, Hagness M, Lassen K, Line PD, Yaqub S.   +7 more
europepmc   +1 more source

Toward Personalized Theranostics: A Modular PET Platform for Antibody‐Based Imaging and Therapy

Advanced Science, EarlyView.
This modular, site‐specific antibody platform enables customizable conjugates for PET imaging and therapy. Interchangeable payloads – including radiometals, cytotoxics, and fluorophores – support adaptable, multimodal applications with limited off‐target effects. In vivo, the DFO/DOTAGA bischelate immunoconjugate provided clear tumor delineation in PET/
Delphine Vivier, Megane Grah Kple, Julen Ariztia, Marion Leroux, Mathieu Moreau, Michael Claron, Maxime Cheveau, Adam Laouafa, Agnieszka Kownacka, Camille Petitot, John Simonet, Alexandre M. M. Dias, Sophie Poty, Charles Truillet, Bertrand Collin, Alexandra Oudot, Franck Denat   +16 more
wiley   +1 more source

Prognostic Significance of Number of Liver Metastases in Patients With Advanced Pancreatic Cancer Receiving Nab-paclitaxel Plus Gemcitabine. [PDF]

Cancer Diagn Progn
Iede K, Yamada T, Takayama H, Sasaki M, Ishida T, Yamashita M, Mokutani Y, Tanida T, Matsuyama J, Nakata K, Tominaga S.   +10 more
europepmc   +1 more source

Mepce Restrains Ferroptosis in Prostate Cancer Through 7SK–P‐TEFb Pause Control

Advanced Science, EarlyView.
Genome‐wide CRISPR screening identifies MEPCE as a pause‐control regulator that restrains ferroptosis in prostate cancer. MEPCE loss releases P‐TEFb/CDK9 from 7SK snRNP control, enhances RNAPII Ser2 phosphorylation, and accelerates NRF2‐HMOX1‐driven labile iron accumulation and lipid peroxidation, revealing a transcriptional kinetic gate that lowers ...
Tongtong Zhang, Xiangyang Zhan, Jiexiang Zhang, Mingyue Tan, Chuanmin Chu, Guanqun Ju, Xinyu Zhai, Jianyi Gu, Huirong Zhu, Dongliang Xu   +9 more
wiley   +1 more source

Yttrium-90 radioembolization for neuroendocrine liver metastases: baseline vascularity predicts cytoreduction efficacy. [PDF]

PLoS One
Frisch A, Kahn J, Collettini F, Steinhagen P, Fehrenbach U, Gebauer B, Amthauer H, Schatka I, Herzler P, Wieners G, Lüdemann WM.   +10 more
europepmc   +1 more source

GM‐CSF Promotes Neutrophil PD‐L1 Expression Through the VEGFR‐2/STAT6/CSF2 Signaling Axis in Oral Squamous Cell Carcinoma

Advanced Science, EarlyView.
VEGFR‐2 signaling in OSCC activates Src–STAT6‐dependent CSF2 transcription, driving tumor‐derived GM‐CSF secretion. GM‐CSF programs neutrophils to express PD‐L1 through STAT5–mTOR/S6K signaling, suppressing cytotoxic CD8+ T cells. This pathway reveals a tumor–neutrophil immune checkpoint circuit that limits anti‐PD‐1 responsiveness in OSCC.
Fangxing Zhu, Yuanhe You, Yiyi Zhang, Yibin Dai, Xinyu Zhou, Yong Fu, Xi Lu, Yingying Huang, Zhihang Zhou, Ronghui Xia, Wutong Ju, Zhaoqi Yuan, Laiping Zhong, Tongchao Zhao   +13 more
wiley   +1 more source